Author Correction to: Diabetes Ther /s
|
|
|
- Adrian Shepherd
- 5 years ago
- Views:
Transcription
1 Diabetes Ther (2018) 9: AUTHOR CORRECTIO Author Correction: Effectiveness and Safety of a ovel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, on-randomized, Controlled Study Sarah J. Hallberg. Amy L. McKenzie. Paul T. Williams. asir H. Bhanpuri. Anne L. Peters. Wayne W. Campbell. Tamara L. Hazbun. Brittanie M. Volk. James P. McCarter. Stephen D. Phinney. Jeff S. Volek Published online: March 5, 2018 Ó The Author(s) This article is an open access publication Author Correction to: Diabetes Ther The original version of this article unfortunately contained a mistake. The presentation of Table 1 and ESM 1 have been published incorrectly. Corrected units have been provided for LDL-C values. The corrected Table 1 in text is given below and ESM Table 1 is available online. The original article can be found online at org/ /s Electronic supplementary material The online version of this article ( contains supplementary material, which is available to authorized users. S. J. Hallberg T. L. Hazbun Medically Supervised Weight Loss, Indiana University Health Arnett, Lafayette, I, USA S. J. Hallberg A. L. McKenzie (&). H. Bhanpuri B. M. Volk J. P. McCarter S. D. Phinney J. S. Volek Virta Health, San Francisco, CA, USA amy@virtahealth.com P. T. Williams Independent Consultant, Lafayette, CA, USA W. W. Campbell Department of utrition Science, Purdue University, West Lafayette, I, USA J. P. McCarter Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA J. S. Volek Department of Human Sciences, The Ohio State University, Columbus, OH, USA A. L. Peters Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
2 614 Diabetes Ther (2018) 9: Table 1 Baseline characteristics of the recruited sample, completers, and participants with by treatment arm Age (years) CCI-all education a (8.35) (8.35) (8.25) 2.0 ± 1.37 Usual care a (9.52) (9.62) (6.85) ± 2.53* care b 1.42 ± ± 1.23* ± 2.6* Female (%) CCI-all education a ± ± ± ± 7.28 Usual care a ± ± ± ± care b 8.17 ± ± ± 17.8 African American (%) CCI-all education a ± ± ± ± 5.05 Usual care a ± ± ± ± 0.0 care b 6.87 ± ± 1.6à ± 4.78* Years with type 2 diabetes CCI-all education a (7.22) (7.28) (6.97) ± 1.16 Usual care a (7.32) (7.32) ot collected care b 0.59 (0.9) 0.56 ± 1.0 Beta-hydroxybutyrate CCI-all education a (0.15) (0.15) (0.16) ± 0.02 Usual care a (0.13) (0.12) (0.15) ± 0.03 care b 0.02 ± ± ± 0.04 Hemoglobin A 1c (mmol mol -1 ) CCI-all education a (16.4) (15.3) (19.57) ± 2.73 Usual care a (19.24) (19.89) (14.87) ± 4.48
3 Diabetes Ther (2018) 9: ± ± ± 4.59* care b Hemoglobin A 1c (%) CCI-all education a (1.50) (1.4) (1.79) ± 0.25 Usual care a (1.76) (1.82) (1.36) 0.60 ± 0.41 care b ± ± ± 0.42* Fasting glucose CCI-all education a (3.41) (3.28) (3.83) ± 0.56 Usual care a (4.03) (3.96) (4.5) 0.21 ± 1.25 care b 0.25 ± ± ± 1.27 Insulin all (pmol L -1 ) CCI-all education a (165.85) (167.17) (163.21) ± 24.1 Usual care a (172.58) (187.93) (119.18) ± ± ± ± care b C-peptide (nmol L -1 ) CCI-all education a (0.71) (0.72) (0.69) 0.07 ± 0.1 Usual care a (0.82) (0.82) (0.84) ± 0.22 care b 0.07 ± ± ± 0.21 HOMA-IR (insulin derived), all CCI-all education a (13.14) (12.75) (14.12) ± 1.99 Usual care a (9.12) (10.05) (6.03) 2.36 ± 1.86 care b 1.16 ± ± ± 2.17
4 616 Diabetes Ther (2018) 9: HOMA-IR (C-peptide derived) CCI-all education a (7.15) (6.26) (9.04) ± 1.19 Usual care a (7.26) (7.70) (6.33) ± 1.69 care b 0.36 ± ± ± 1.67 Weight-clinic (kg) CCI-all education a (25.94) (24.62) (29.01) ± 3.85 Usual care a (22.15) (22.18) (21.86) 6.84 ± 6.42 care b ± ± ± 6.76 BMI (kg m -2 ) CCI-all education a (8.81) (7.88) (10.75) ± 1.39 Usual care a (7.26) (7.62) (4.8) 2.48 ± 1.58 care b 3.7 ± 0.97à 2.73 ± ± 1.8 Systolic blood pressure (mmhg) CCI-all education a (14.09) (14.54) (12.84) 2.05 ± 1.84 Usual care a (13.61) (12.65) (17.49) ± 5.28 care b 2.14 ± ± 1.88* ± 5.27 Diastolic blood pressure (mmhg) CCI-all education a (8.25) (8.05) (8.67) ± 1.17 Usual care a (8.93) (8.07) (11.95) ± 3.59 care b 0.09 ± ± ± 3.6 Total cholesterol CCI-all education a (1.07) (1.03) (1.15) ± 0.17 Usual care a (1.19) (1.26) (0.93) ± 0.27
5 Diabetes Ther (2018) 9: ± ± ± 0.26 care b LDL-cholesterol CCI-all education a (0.85) (0.84) (0.86) ± 0.13 Usual care a (0.94) (0.98) (0.85) ± 0.23 care b 0.03 ± ± ± 0.21 Apo B (g L -1 ) CCI-all education a (0.29) (0.28) (0.31) ± 0.04 Usual care a (0.28) (0.3) (0.24) ± 0.07 care b ± ± ± 0.07 HDL-C CCI-all education a (0.35) (0.36) (0.32) 0.02 ± 0.05 Usual care a (0.29) (0.29) (0.29) ± 0.08 care b 0.12 ± ± ± 0.08 Triglycerides CCI-all education a (1.62) (1.73) (1.25) 0.15 ± 0.2 Usual care a (4.53) (5.17) (1.56) 0.64 ± 0.76 care b ± 0.52* ± ± 0.38* Total/HDL-cholesterol CCI-all education a (1.7) (1.72) (1.65) ± 0.25 Usual care a (2.42) (2.63) (1.72) 0.27 ± 0.52 care b ± 0.29* ± 0.36* ± 0.44 hsc-reactive protein (nmol L -1 ) CCI-all education a (138.0) (153.05) (62.1) ± 13.81
6 618 Diabetes Ther (2018) 9: Usual care a (82.1) (86.95) (73.81) ± ± ± ± care b ALT (lkat L -1 ) CCI-all education a (0.38) (0.41) (0.27) 0.05 ± 0.05 Usual care a (0.33) (0.34) (0.29) ± 0.09 care b 0.05 ± ± ± 0.08 AST (lkat L -1 ) CCI-all education a (0.25) (0.28) (0.15) 0.04 ± 0.03 Usual care a (0.32) (0.35) (0.16) ± 0.06 care b ± ± ± 0.05 Alkaline phosphatase (lkat L -1 ) CCI-all education a (0.37) (0.37) (0.36) 0.01 ± 0.05 Usual care a (0.44) (0.45) (0.38) 0.09 ± 0.11 care b ± ± ± 0.11 Serum creatinine (lmol L -1 ) CCI-all education a (21.22) (20.33) (24.75) ± 3.54 Usual care a (22.1) (20.33) (25.64) ± 7.07 care b ± ± ± 7.07 BU CCI-all education a (2.34) (2.15) (2.96) 0.16 ± 0.42 Usual care a (2.23) (1.86) (3.52) ± 0.94 care b 0.3 ± ± ± 0.99
7 Diabetes Ther (2018) 9: egfr (ml s -1 m -2 ) CCI-all education a (0.23) (0.22) (0.25) 0.02 ± 0.04 Usual care a (0.23) (0.22) (0.28) 0.08 ± 0.08 care b 0.02 ± ± ± 0.08 Anion gap CCI-all education a (1.67) (1.7) (1.53) ± 0.24 Usual care a (1.82) (1.82) (1.89) ± 0.53 care b ± ± ± 0.53 Uric acid (lmol L -1 ) CCI-all education a (86.85) (86.25) (89.82) 2.38 ± Usual care a (87.44) (85.66) (98.75) ± care b ± ± ± TSH (miu L -1 ) CCI-all education a (1.74) (1.79) (1.55) ± 0.24 Usual care a (1.16) (1.16) (1.03) 0.71 ± 0.3* care b 0.36 ± 0.17* 0.21 ± ± 0.33 Free T4 (pmol L -1 ) CCI-all education a (2.19) (2.32) (2.19) 0.26 ± 0.39 Usual care a (3.73) (3.86) (2.32) 0.39 ± 0.77 care b 0.51 ± ± ± 0.64 Any diabetes medication, excluding metformin (%) CCI-all education a ± ± ± ± 8.00 Usual care a ± ± ± ± care b ± ± 6.39* 6.49 ± 15.08
8 620 Diabetes Ther (2018) 9: Sulfonylurea (%) CCI-all education a ± ± ± ± 6.74 Usual care a ± ± ± ± care b ± ± ± Insulin (%) CCI-all education a ± ± ± ± 7.87 Usual care a ± ± ± (1.91)à care b ± ± 6.43à ± 12.74* Thiazolidinedione (%) CCI-all education a ± ± ± ± 0.91* Usual care a ± ± ± ± 1.36 care b 0.38 ± ± ± 0.0 SGLT-2 (%) CCI-all education a ± ± ± ± 4.81 Usual care a ± ± ± ± 8.06 care b ± ± ± 8.13* DPP-4 (%) CCI-all education a ± ± ± ± 4.79 Usual care a ± ± ± ± 7.60 care b 1.87 ± ± ± 8.13 GLP-1 (%) CCI-all education a ± ± ± ± 5.96 Usual care a ± ± ± ± 8.14 care b ± ± ± 8.82
9 Diabetes Ther (2018) 9: Metformin (%) CCI-all education a ± ± ± ± 7.53 Usual care a ± ± ± ± care b ± ± ± See Table S1 (electronic supplemental materials) for CCI-web, CCI-onsite, and additional comparisons a Mean and standard deviations for continuous variables, percents and standard errors for categorical variables b Difference between means or percentages ± 1 standard error of the difference. Significant baseline difference between means or percentages at 0.05[P C 0.01 (*); 0.01[P C ( ); 0.001[P C (à); and P\ ( ) OPE ACCESS This article is distributed under the terms of the Creative Commons Attribution-onCommercial 4.0 International License ( commons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study
Diabetes Ther (2018) 9:583 612 https://doi.org/10.1007/s13300-018-0373-9 ORIGINAL RESEARCH Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label,
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery
SITA 100 mg (n = 378)
Supplementary Table 1. Summary of Sulfonylurea Background Therapy at Baseline and During the Treatment Period. Sulfonylurea at baseline, n (%) SITA 100 mg (n = 378) CANA 300 mg (n = 377) Total (N = 755)
Supplementary Table 1. Patient demographics and baseline characteristics (treated patients).
Supplementary Table 1. Patient demographics and baseline characteristics (treated patients). Placebo (n=188) 10 mg (n=186) 25 mg (n=189) Total (n=563) Gender, n (%) Male 75 (40) 97 (52) 84 (44) 256 (45)
Clinical Trial Update: 6 month outcomes in patients with type 2 diabetes
Clinical Trial Update: 6 month outcomes in patients with type 2 diabetes Amy L. McKenzie, Nasir Bhanpuri, James McCarter Virta Health Nearly 30 million Americans 1 and over 400 million people worldwide
Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures
Supplementary Data Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures Quintiles of Systolic Blood Pressure Quintiles of Diastolic Blood Pressure Q1 Q2
Supplementary Table 1. Criteria for selection of normal control individuals among healthy volunteers
Supplementary Table 1. Criteria for selection of normal control individuals among healthy volunteers Medical parameters Cut-off values BMI (kg/m 2 ) 25.0 Waist (cm) (Men and Women) (Men) 85, (Women) 90
Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Table S2: Anthropometric, clinical, cardiovascular and appetite outcome changes over 8 weeks (baseline-week 8) by snack group
Table S1: Nutrient composition of cracker and almond snacks Cracker* Almond** Weight, g 77.5 g (5 sheets) 56.7 g (2 oz.) Energy, kcal 338 364 Carbohydrate, g (kcal) 62.5 12.6 Dietary fiber, g 2.5 8.1 Protein,
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
Evidence for a new category of diabetes care: Reversal James McCarter MD PhD, Head of Research, Virta Health
Evidence for a new category of diabetes care: Reversal James McCarter MD PhD, Head of Research, Virta Health September 20, 2018 Why manage when you can reverse type 2 diabetes without medication or surgery?
Supplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
egfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
Deprivation Study. The Freiburg Study
The Freiburg Study Deprivation Study Free Radicals Inflammation (hs-crp) Blood Pressure (Systolic, Diastolic) Blood Lipids (Cholesterol, Triglycerides) Energy Utilization (Heart Rate) Sugar Metabolism
Supplementary Online Content
Supplementary Online Content Anagnostou E, Aman MG, Handen BL, et al. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autistic spectrum disorder:
Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
Journal of Obesity & Metabolic Syndrome 2017;26:107-113 Original Article pissn 2508-6235 eissn 2508-7576 Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
Diabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
A Method for Analyzing Commonalities in Clinical Trial Target Populations
A Method for Analyzing Commonalities in Clinical Trial Target Populations Zhe (Henry) He 1, Simona Carini 2, Tianyong Hao 1, Ida Sim 2, and Chunhua Weng 1 1 Department of Biomedical Informatics, Columbia
Wayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
INTRODUCTION TO NUTRITIONAL KETOSIS AND CLINICAL APPLICATIONS
INTRODUCTION TO NUTRITIONAL KETOSIS AND CLINICAL APPLICATIONS Jeff S. Volek, Ph.D., R.D. Professor Department of Human Sciences Kinesiology Program Columbus, OH 43210 volek.1@osu.edu LEARNING OBJECTIVES
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: in people treated for type 2 diabetes with multiple daily insulin
ASSeSSing the risk of fatal cardiovascular disease
ASSeSSing the risk of fatal cardiovascular disease «Systematic Cerebrovascular and coronary Risk Evaluation» think total vascular risk Assess the risk Set the targets Act to get to goal revised; aupril
Know Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
Chemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-30 U/L 10-30 U/L 10-20 U/L Albumin 0-6 days 6 days - 37 months 37 months - 7 years 7-20 years 2.6-3.6 g/dl 3.4-4.2 g/dl
Chemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-25 U/L 10-35 U/L 10-30 U/L 10-25 U/L 10-30 U/L 10-35 U/L 10-25 U/L 10-35 U/L 10-25 U/L 10-20 U/L 10-35 U/L Albumin 0-6
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
DIABETES AND LABORATORY TESTS. Author: Josephine Davis
DIABETES AND LABORATORY TESTS Author: Josephine Davis LAB TESTS Think twice before you test. What is the reason for testing? Laboratory tests are generally requested in primary care for one of the following
Complete Medical History
Lab Results for Ben Greenfield Last Test Date: Your medical history is not complete. Complete Medical History Complete Medical History What's Next Blood Draw Blood draw scheduled Complete your medical
Efficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
The Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
Non-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
Multiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
ABSTRACT ORIGINAL RESEARCH. Ichiro Nakamura. Hiroshi Maegawa. Kazuyuki Tobe. Satoshi Uno
Adv Ther (2019) 36:923 949 https://doi.org/10.1007/s12325-019-0895-1 ORIGINAL RESEARCH Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG
SYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
S150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
Fullerton Healthcare Screening Centres
Fullerton Healthcare Screening Centres Fullerton Healthcare Screening Centre @ Ngee Ann City The Penthouse, #26-02 Ngee Ann City Tower B, 391B Orchard Road, Singapore 238874 Operating hours: Monday - Friday
iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L
Diabetes Ther (2018) 9:373 382 https://doi.org/10.1007/s13300-017-0336-6 BRIEF REPORT iglarlixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post
Sect S io ecn ti 1 o : n Trend 1: Tres nds
Section 1: 1: Trends 1 Patients in the Diabetes Register 2 Gender of Patients with Diabetes 2 Age of Patients with Diabetes 3 Diabetes Type 3 Duration of Diabetes 4 Weight Control 5 Hemoglobin A1c 6 Blood
SUPPLEMENTARY DATA. Supplementary Table 1. Baseline Patient Characteristics
Supplementary Table 1. Baseline Patient Characteristics Normally distributed data are presented as mean (±SD), data that were not of a normal distribution are presented as median (ICR). The baseline characteristics
Tables of Normal Values (As of February 2005)
Tables of Normal Values (As of February 2005) Note: Values and units of measurement listed in these Tables are derived from several resources. Substantial variation exists in the ranges quoted as normal
A Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
Nature Medicine: doi: /nm.3891
Supplementary Figure 1. Subjective responses. Thermal sensation, thermal comfort and self-reported shivering, determined at several time points (from t = min until t = 36 min) after entering the cold room,
(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
Study Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
Application of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
Section 1: 1: Trends. Section 2: 2: Comparisons to to Overall Portland Area Area Results for for
Section 1: 1: Trends 1 Patients in the Diabetes Register 2 Gender of Patients with Diabetes 2 Age of Patients with Diabetes 3 Diabetes Type 3 Duration of Diabetes 4 Weight Control 5 Hemoglobin A1c 6 Blood
28-Aug-15. RACGP guidelines 2014/15. ADS guidelines Part 1 T2D Guidelines. Part 2 What comes after metformin?
Part 1 T2D Guidelines Oral therapies in T2 diabetes Dr Gary Kilov T2D Guidelines - What s New? What comes after metformin? 1 RACGP guidelines 2014/15 ADA-EASD: Anti-Hyperglycaemic therapy 2015 3 4 Inzucchi
CASE A2 Managing Between-meal Hypoglycemia
Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common
Supplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
ABFM Diabetes SAM Part 4
ABFM Diabetes SAM Part 4 37. A 55-year-old male with type 2 diabetes mellitus has a chronic history of reduced libido and erectile dysfunction. On examination you note hepatomegaly and mild testicular
23-Aug-2011 Lixisenatide (AVE0010) - EFC6014 Version number: 1 (electronic 1.0)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of metformin
SUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.*
Supplementary Table S1. Clinical characteristics of the study subjects.* T2D ND n (F/M) 66 (21/45) 25 (7/18) Age (years) 61.8 ± 6.9 49.4 ± 7.3 # Body weight (kg) 95 ± 16 105 ± 13 # Body mass index (kg.
M Series. Health Screening Just Got A Whole Lot Easier EARLY DETECTION BETTER MANAGEMENT IMPROVED OUTCOMES
M Series Health Screening Just Got A Whole Lot Easier EARLY DETECTION BETTER MANAGEMENT IMPROVED OUTCOMES ABOUT MINMED We are a progressive medical group that enlarges organically by growing constantly,
Changing Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
Ct=28.4 WAT 92.6% Hepatic CE (mg/g) P=3.6x10-08 Plasma Cholesterol (mg/dl)
a Control AAV mtm6sf-shrna8 Ct=4.3 Ct=8.4 Ct=8.8 Ct=8.9 Ct=.8 Ct=.5 Relative TM6SF mrna Level P=.5 X -5 b.5 Liver WAT Small intestine Relative TM6SF mrna Level..5 9.6% Control AAV mtm6sf-shrna mtm6sf-shrna6
Total Cholesterol A Type of Fat. LDL "Bad" Cholesterol. HDL "Good" Cholesterol. Triglycerides Type of Fat. vldl-c Precursor to LDL Cholest
Lab Results for Ben Greenfield Last Test Date: 2013-08-13 Let us know what you think How likely are you to recommend WellnessFX to a friend or colleague? 1 2 3 4 5 6 7 Not at all likely Neutral Extremely
Hamilton Regional Laboratory Medicine Program
Created: April 2002 of Review: February 2004 of Review: June 2006 of Review: July 2007, St. Joseph s Healthcare went live with Meditech as of June18, 2007. of Review: August 2009 of Review: December 2011;
Get to know yourself better. Attend our health screening event.
Get to know yourself better. Attend our health screening event. Putting your knowledge to action is Powerful. Get the information and guidance you need with the Wellness Screening Program. 1 SIMPLE ACTION
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution
Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein
Supplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial
Professor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
SUPPLEMENTARY DATA. Supplementary Figure 1. PubMed
Supplementary Figure 1. PubMed ((((((type 2 diabetes[title/abstract] OR type II diabetes[title/abstract] OR non-insulin diabetes[title/abstract]) AND (monounsaturated[title/abstract] OR polyunsaturated[title/abstract]
Type 2 diabetes in Tuvalu: A drug use and chronic disease management evaluation. Prepared for the Ministry of Health, Tuvalu.
Type 2 diabetes in Tuvalu: A drug use and chronic disease management evaluation Prepared for the Ministry of Health, Tuvalu. 2012 Investigator Alexander Bongers Intern pharmacist, Royal Melbourne Hospital,
Supplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC
Supplementary Table 1. The distribution of IFNL rs12979860 and rs8099917 and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC rs12979860 (n=3129) CC 1127 1145.8 CT 1533 1495.3 TT
1. Pharmacokinetics. When is steady state achieved? Steady-state was reached after 4 to 5 days of once-daily dosing with Sulisent 100 mg to 300mg.
1. Pharmacokinetics How is Sulisent metabolized? Sulisent has a novel mechanism of action that targets the kidneys and allows for excess glucose excretion resulting in urinary calorie loss. Sulisent is
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis
Elmer ress Original Article J Clin Med Res. 2016;8(3):237-243 Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis Hisayuki
Adult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
WSLH. Calibration Verification/ Linearity Products. roficiency. esting. Products provided in partnership with:
WSLH PT roficiency esting Calibration Verification/ Linearity Products Products provided in partnership with: www.wslhpt.org 800-462-5261 PTService@slh.wisc.edu General Chemistry Ammonia/Ethanol - 5 x
HEALTH SCREEN CARE. VIGNE Healthcare provides a comprehensive Health Screening Package of EXCLUSIVE HEALTH SCREENING EXPERIENCE
HEALTH SCREEN CARE VIGNE Healthcare provides a comprehensive Health Screening Package of Silver Gold Platinum Cancer EXCLUSIVE HEALTH SCREENING EXPERIENCE Meet & Greet Medical Review with Doctor Appointment
CAPE FEAR VALLEY PHYSICIAN REFERRAL DIRECTORY
CAPE FEAR VALLEY PHYSICIAN REFERRAL DIRECTORY 2 0 0 6-2 0 0 7 Orthopaedics Christopher J. Barnes, MD Ohio State University College of Medicine, Columbus, OH Duke University Medical Center, Durham, NC Southern
SCIENTIFIC STUDY REPORT
PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established
Bariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes
The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,
Research Data Available
Research Data Available Main Questionnaire General Topic Socio-economic status Occupational exposure Physical activity Mobile phone usage Sleeping patterns smoking Childhood conditions/illnesses/family
Get to know yourself better. Attend our health screening event.
Gateway Technical College Get to know yourself better. Attend our health screening event. Putting your knowledge to action is Powerful. Get the information and guidance you need with the Wellness Screening
CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia
CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia Javier Carrasco, MD, PhD Juan Ramón Jiménez Hospital University of Huelva, Spain Case Study: Medical and Social History A 60 years old female
Clinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE Clinical study on the therapeutic efficacy of the dipeptidyl peptidase 4 inhibitors, in type 2 diabetes PhD Thesis Abstract Key words:
Study of fixed dose combination for the management of cardiovascular diseases
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-331; ISSN (Online): 2321-386 Available online at: http://www.wjpsonline.org/ Original Article Study of fixed dose combination for the management
Statistical Analysis Plan
Statistical Analysis Plan A randomised controlled trial evaluation of the effectiveness of three minimal human contact interventions to promote fitness and physical activity in an occupational health setting.
Supplementary Information for: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative.
Supplementary Information for: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. Authors: Pamela Piscitelli 1, Francesca Viazzi 2 ; Paola Fioretto
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
Vipul Lakhani, MD Oregon Medical Group Endocrinology
Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment
ROTUNDA HOSPITAL DEPARTMENT OF LABORATORY MEDICINE
This active test table informs the user of Biochemistry tests available in house. s referred to other sites are recorded in the Referred Table. Issue date: 4 TH April 2016 Contact Phone Number ext.1345/2522
Case study for CME Diabetes up-to-date management
Case study for CME Diabetes up-to-date management Dr Ole Schmiedel, MRCP MD FRACP Physician and Endocrinologist Service Clinical Director Auckland Diabetes Centre GP referral to Auckland Diabetes Centre
Energy Balance Equation
Energy Balance Equation Intake Expenditure Hunger Satiety Nutrient Absorption Metabolic Rate Thermogenesis Activity Eat to Live! Live to Eat! EAT TO LIVE Intake = Expenditure Weight Stable LIVE TO EAT
Diabetes Audit Results, Portland Area, Site-Specific Trends
Site-Specific Trends The following report contains information from your program's annual diabetes audit submission to the Indian Health Service over the past few years. The report was prepared for your
DM type. Diagnostic method of DR. fluorescein angiography; Ophthalmoscopy. ophthalmoscopic examination. fundus photography; Ophthalmoscopy
2012 Informa USA, Inc. DOI: 10.3109/13816810.2012.675398 Online supplementary material published in conjunction with S. Zhao et al.., Nitric oxide synthase 3 (NOS3) 4b/a, T-786C and G894T polymorphisms
Supplementary Note Details of the patient populations studied Strengths and weakness of the study
Supplementary Note Details of the patient populations studied TVD and NCA patients. Patients were recruited to the TVD (triple vessel disease) group who had significant coronary artery disease (defined
SGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
NIH Public Access Author Manuscript Pediatr Obes. Author manuscript; available in PMC 2015 October 01.
NIH Public Access Author Manuscript Published in final edited form as: Pediatr Obes. 2014 October ; 9(5): e103 e107. doi:10.1111/ijpo.237. Depressive Symptoms are Associated with Fasting Insulin Resistance
*** To get the most out of this report and the consultation, send us blood test results that cover as many of the following markers as possible:
Rick Gold, Certified FDN Practitioner Gold Functional Wellness, Inc. Web: http://goldfunctionalwellness.com/ Phone: (561)270-6364 Email: Rick@goldfunctionalwellness.com Schedule a consultation: https://snapappointments.com/listing/38c
Supplementary Online Content
Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.
Obesity and Insulin Resistance According to Age in Newly Diagnosed Type 2 Diabetes Patients in Korea
https://doi.org/10.7180/kmj.2016.31.2.157 KMJ Original Article Obesity and Insulin Resistance According to Age in Newly Diagnosed Type 2 Diabetes Patients in Korea Ju Won Lee, Nam Kyu Kim, Hyun Joon Park,
journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract
The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,